ANRO Fail-to-Deliver
Alto Neuroscience, Inc. (ANRO) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $730.0M, listed on NYSE, employing roughly 76 people, carrying a beta of 1.65 to the broader market. Alto Neuroscience, Inc. Led by Amit Etkin, public since 2024-02-02.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
- Latest Date
- 2026-04-21
- Latest FTD Quantity
- 12.3K
- Latest Price
- $27.33
- 30-Day Avg FTD
- 7.9K
- 30-Day Total FTD
- 236.2K
Showing 30 days of SEC fail-to-deliver data for Alto Neuroscience, Inc..
Learn how fails-to-deliver is reported and how to read the data →
Frequently asked ANRO fail to deliver questions
- What is the latest ANRO fail-to-deliver count?
- As of Apr 21, 2026, Alto Neuroscience, Inc. (ANRO) fail-to-deliver quantity is 12.3K shares, with a 30-day average of 7.9K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
- What is the FTD aggregate net balance?
- FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
- How do ANRO FTDs affect options pricing?
- Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.